Global Antipsychotic Drugs Market is Expected to Grow at a CAGR of 5.70 % by 2030

Pune, India, 2023 /MRFR Press Release/- Market research future published a half-cooked research report on global Antipsychotic Drugs market. Market Research Future (MRFR) has published a cooked research report on the “Global Antipsychotic Drugs Market” that contains information from 2023 to 2030. 

Market Highlights

Global Antipsychotic Drugs Market is accounted to register a CAGR of 5.70% during the forecast period and is estimated to reach USD 33.5 Billion by 2030.

Antipsychotic drugs, also known as neuroleptic drugs, are a class of medications primarily used to manage symptoms of psychosis. Psychosis refers to a group of mental disorders characterized by a loss of contact with reality, which can include symptoms such as hallucinations, delusions, disorganized thinking, and a lack of insight. Antipsychotic drugs work by modulating the activity of certain neurotransmitters in the brain, particularly dopamine, serotonin, and norepinephrine. By blocking or reducing the effects of dopamine, these medications help alleviate psychotic symptoms and stabilize mood.

Key Players

MRFR recognizes the following companies as the key players in the Global Antipsychotic Drugs Market— Johnson and Johnson, GlaxoSmithKline Plc, Pfizer Inc, AstraZeneca, Bristol-Myers Squibb, Eli Lily & Co.

Segment Analysis

The Global Antipsychotic Drugs Market has been segmented based on Generation, Type, and Application.

Based on Generation, the market is segmented into First Generation, Second Generation. The First Generation category dominates the Antipsychotic Drugs market due to its long history of use and established efficacy in treating psychosis.

Based on Type, the market is segmented into Atypical Antipsychotic, Miscellaneous Antipsychotics Agents. The Atypical Antipsychotic category dominates the Antipsychotic Drugs market due to their improved tolerability and a broader spectrum of action compared to typical antipsychotics.

Based on Application, the market is segmented into Schizophrenia, Anxiety, and Bipolar Disorder. The Schizophrenia category dominates the Antipsychotic Drugs market due to the high prevalence and chronic nature of schizophrenia, requiring long-term treatment with antipsychotic medications.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Antipsychotic Drugs Market Research Report

Regional Analysis

The Global Antipsychotic Drugs Market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Global Antipsychotic Drugs Market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The Global Antipsychotic Drugs Market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World's Global Antipsychotic Drugs Market comprises of Middle East, Africa, and Latin America.

In 2022, the Antipsychotic Drugs market in North America reached USD 9.84 billion, holding a dominant share of approximately 45.80%, and is projected to exhibit a substantial compound annual growth rate (CAGR) throughout the study period. This growth is fueled by factors such as a well-established healthcare infrastructure, favorable regulatory framework, increasing prevalence of mental disorders, and government support. Additionally, the region experiences a significant burden of mental illness and schizophrenia, contributing to the market's expansion.

Europe follows North America as the second-largest market for Antipsychotic Drugs, driven by a growing awareness of mental illness and its high prevalence within the region.

The Asia Pacific Antipsychotic Drugs Market is anticipated to witness the fastest CAGR from 2022 to 2030. This can be attributed to a substantial population suffering from chronic and mental illnesses, resulting in increased market demand. The region is expected to experience a high CAGR due to rising social awareness about mental illness and related disorders. Furthermore, growing awareness regarding mental health is also driving the demand for antipsychotic drugs in the market.

Key Findings of the Study

• The Global Antipsychotic Drugs Market is expected to reach USD 33.5 Billion by 2030, at a CAGR of 5.70% during the forecast period.


• The North America Antipsychotic Drugs market reached USD 9.84 billion, holding a share of approximately 45.80%, and is projected to experience a significant CAGR growth during the study period. This growth is driven by factors such as a well-established healthcare infrastructure, favorable regulatory framework, increasing prevalence of mental disorders, and government support in the region.


• Based on the Generation, the Market has been segmented into First Generation holding the largest market in 2023.


• Johnson and Johnson, GlaxoSmithKline Plc, Pfizer Inc, AstraZeneca, Bristol-Myers Squibb, Eli Lily & Co.